India's DMPLOI - Jobs & Networking App
Global pharmaceutical major Lupin Limited (Lupin) has announced the launch of Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen, in the United States.
The product is bioequivalent to Victoza® Injection (Novo Nordisk Inc.) and is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
Expanding Access to Essential Diabetes Therapies
Liraglutide Injection (RLD Victoza®) represents a significant addition to Lupin’s U.S. injectable portfolio. According to IQVIA MAT (August 2025), the product had an estimated annual sale of USD 350 million in the U.S., highlighting the commercial importance of this launch.
Strategic Milestone for Lupin
Commenting on the development, Spiro Gavaris, President – U.S. Generics, Lupin, said:
“We are pleased to launch Liraglutide Injection in the U.S. This marks a significant milestone in enhancing our portfolio of complex injectables and highlights our continued commitment to making essential therapies more accessible for patients.”
The launch strengthens Lupin’s position in the complex generics and injectables segment—key growth areas for the company in the U.S. market.
About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with a strong presence across over 100 markets worldwide. The company develops and markets a broad range of branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients (APIs).
Lupin has established leadership in several therapy areas, including:
- Respiratory
- Cardiovascular
- Anti-diabetic
- Anti-infective
- Gastrointestinal
- Central nervous system
- Women’s health
The company operates 15 state-of-the-art manufacturing facilities and 7 research centers globally, supported by a workforce of over 24,000 professionals.
